<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04560790</url>
  </required_header>
  <id_info>
    <org_study_id>JYMS-CXL#02</org_study_id>
    <nct_id>NCT04560790</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis</brief_title>
  <official_title>CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy Assisted Corneal Transplantation in the Treatment of Refractory Viral Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai BDgene Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai BDgene Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of a single&#xD;
      escalating doses of BD111 CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy administered&#xD;
      via corneal injection in participants with refractory herpetic viral keratitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single ascending dose study of BD111 in adult (ages 18 to 70)&#xD;
      participants with refractory herpetic viral keratitis. Approximately 6 participants will be&#xD;
      enrolled.BD111 is a novel gene editing product designed to clear Herpes simplex virus type I&#xD;
      (HSV-1) that results in herpetic stromal keratitis in both acute and recurrent infection&#xD;
      models which is the leading factor for infectious blindness.&#xD;
&#xD;
      The follow-up period was 360 days, and the patients will be followed up 3±1 days, 7±2 days,&#xD;
      30±7 days, 90±14 days, 180±21 days, and 360+31 days after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group target value: Since there is no similar products approved on the market and there is no similar comparative treatment methods, the single group target value method is adopted</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of dose limiting toxicities</measure>
    <time_frame>24 months</time_frame>
    <description>Observe and record AE,SAE incidence of dose limiting toxicities related with BD111 administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of maximum tolerated dose</measure>
    <time_frame>24 months</time_frame>
    <description>Observe and record AE,SAE at maximum tolerated dose when occurs dose limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance effective of HSV-1 genome</measure>
    <time_frame>24 months</time_frame>
    <description>Judge HSV-1 genome clearance effective according to DNA sequencing results by methods of Plaque assay,Elisa,PCR etc.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of reblindness in 6 participants with Refractory Viral Keratitis</measure>
    <time_frame>24 months</time_frame>
    <description>180 days after corneal surgical, calculate rate of reblindness of treated eye in 6 participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grafted corneal survival time</measure>
    <time_frame>24 months</time_frame>
    <description>Observe the survival time of grafted corneal in subjects, whether the grafted corneal is transparency or opacity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual improvement compared with baseline</measure>
    <time_frame>24 months</time_frame>
    <description>Judge the visual recovery progress according to visual examination results on day 3±1，7±2，30±7，90±14，180±21，360±31.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Falling of herpes virus content compared with baseline</measure>
    <time_frame>24 months</time_frame>
    <description>Herpes virus content before and after treatment were determinated by methods of plaque assay,ELISA,PCR etc.Compare the viral content changes with baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Viral Keratitis</condition>
  <condition>Blindness Eye</condition>
  <condition>Herpes Simplex Virus Infection</condition>
  <condition>Cornea</condition>
  <arm_group>
    <arm_group_label>BD111 Adults single group Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD111 Adult single group Dose</intervention_name>
    <description>6 Participants will receive a single group dose administered via corneal injection in the study eye.</description>
    <arm_group_label>BD111 Adults single group Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients (replase) with refractory keratitis caused by herpes virus type I who has had at&#xD;
        least one time failed corneal transplant.&#xD;
&#xD;
          1. Age between 18 to 70 years.&#xD;
&#xD;
          2. No systemic immune eye disease.&#xD;
&#xD;
          3. Good eyelid structure and blink function.&#xD;
&#xD;
          4. Exists the potential of visual recovery by evaluation of ocular structure and&#xD;
             function.&#xD;
&#xD;
          5. Identify patients who are repeatedly infected with HSV-1 virus(only under the&#xD;
             condition that the patients are obviously suffering replase infections，corneal&#xD;
             perforation and need corneal transplantation).&#xD;
&#xD;
          6. No retinal detachment and normal visual function.&#xD;
&#xD;
          7. No history of corneal trauma.&#xD;
&#xD;
          8. Subjects or their legal guardians voluntarily participate in this study, sign informed&#xD;
             consent, good compliance and cooperation with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lacrimal coating and blink function loss.&#xD;
&#xD;
          2. Schirmer's test result is less than 2mm for severe dry eye disease.&#xD;
&#xD;
          3. Pregnant and lactating women (pregnancy defined in this study as positive urine&#xD;
             pregnancy test).&#xD;
&#xD;
          4. Currently is involved in clinical trials of other drugs or medical devices.&#xD;
&#xD;
          5. Active eye infection (including but not limited to: blepharitis, infectious&#xD;
             conjunctivitis, keratitis, sclerotitis, endophthalmitis) in target eye or&#xD;
             contralateral eye within 30 days prior to enrollment.&#xD;
&#xD;
          6. Ocular surface malignant tumor.&#xD;
&#xD;
          7. A history of allergic reaction or allergy to sodium luciferin, allergy to protein&#xD;
             products used for treatment or diagnosis, allergy to ≥ 2 drugs or non-drug factors, or&#xD;
             current allergic disease.&#xD;
&#xD;
          8. current in an infectious disease requiring oral, intramuscular or intravenous&#xD;
             administration.&#xD;
&#xD;
          9. Patients with systemic immune diseases.&#xD;
&#xD;
         10. Any uncontrolled clinical problems (such as severe mental, neurological,&#xD;
             cardiovascular, respiratory and other systemic diseases and malignant neoplasms).&#xD;
&#xD;
         11. Not effective contraception.&#xD;
&#xD;
         12. In uncontrolled hypertension, systolic is no less than 160 mmhg, diastolic is no less&#xD;
             than 100 mmhg.&#xD;
&#xD;
         13. In uncontrolled diabetes, fasting glucose is no less than 10.0umol/L.&#xD;
&#xD;
         14. Renal insufficiency, serum creatinine is more than 133umol/L.&#xD;
&#xD;
         15. Arrhythmia, myocardial ischemia, myocardial infarction (diagnosed by&#xD;
             electrocardiogram).&#xD;
&#xD;
         16. Liver dysfunction, al ANINE aminotransferase and aspartate aminotransferase levels are&#xD;
             higher than 80 IU/L.&#xD;
&#xD;
         17. Platelet level is below 100,000 /uL or above 450,000 /uL.&#xD;
&#xD;
         18. Hemoglobin level is below 10.0g/dL (male) or 9.0g/dL (female).&#xD;
&#xD;
         19. No anticoagulant was used, prothrombin time is higher than 16s, and thrombin time of&#xD;
             activated part is higher than 50s.&#xD;
&#xD;
         20. HIV infection (HIV-positive).&#xD;
&#xD;
         21. Subjects lack compliance with the study or the ability to sign informed consent.&#xD;
&#xD;
         22. There are currently signs of systemic infection, including fever and ongoing&#xD;
             antibiotic treatment (in this study, systemic infection was defined as deviation from&#xD;
             normal values of white blood cells, lymphocytes, and neutrophils on routine blood&#xD;
             tests).&#xD;
&#xD;
         23. Administration of Glucocorticoids and other systemic immunosuppressive drugs.&#xD;
&#xD;
         24. The investigator judges other conditions unsuitable for the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujia Cai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai BDgene Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye &amp; Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes simplex virus type 1 (HSV-1)</keyword>
  <keyword>CRISPR/Cas9 mRNA</keyword>
  <keyword>instantaneous gene editing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT04560790/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

